Dmitry Kravchenko

Title: Dmitry Kravchenko: Innovator in Immunotherapy Assessment

Introduction

Dmitry Kravchenko is a prominent inventor based in Moscow, Russia. He has made significant contributions to the field of immunotherapy, particularly in the assessment of CAR-T therapies. His innovative work focuses on understanding the tumor microenvironment and its implications for patient treatment outcomes.

Latest Patents

Dmitry holds a patent titled "Tumor microenvironment-based methods for assessing CAR-T and other immunotherapies." This patent outlines methods for determining whether a subject is likely to respond to adoptive cell therapies, such as chimeric antigen receptor (CAR) T-cell therapy. The methods involve identifying a subject's tumor microenvironment type based on a molecular-functional expression signature and assessing their likelihood of response to treatment. Additionally, the patent includes methods for determining the lymphoma microenvironment type in patients with Diffuse Large B Cell Lymphoma (DLBCL) and evaluating their prognosis.

Career Highlights

Dmitry is associated with Bostongene Corporation, where he applies his expertise in immunotherapy and molecular biology. His work at the company has positioned him as a key player in advancing cancer treatment methodologies.

Collaborations

Dmitry collaborates with notable colleagues, including Nikita Kotlov and Georgy Sagaradze. Their combined efforts contribute to the ongoing research and development in the field of immunotherapy.

Conclusion

Dmitry Kravchenko's innovative approaches to assessing immunotherapies highlight the importance of understanding the tumor microenvironment in cancer treatment. His contributions are paving the way for more effective therapies and improved patient outcomes.